Compounds > bepridil

bepridil and carvedilol

bepridil has been researched along with carvedilol in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (80.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Keserü, GM1
Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD1
Nagashima, R; Nishikawa, T; Tobita, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Jia, L; Sun, H1
Faller, B; Trunzer, M; Zimmerlin, A1
Sen, S; Sinha, N1
Hashimoto, K; Kanmatsuse, K; Masaki, R; Nakai, T; Ohkubo, K; Okumura, Y; Ozawa, Y; Saito, S; Shindo, A; Sugimura, H; Takagi, Y; Watanabe, I1
Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K1

Trials

2 trial(s) available for bepridil and carvedilol

ArticleYear
Recurrence of atrial fibrillation after internal cardioversion of persistent atrial fibrillation: prognostic importance of electrophysiologic parameters.
    Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:12

    Topics: Action Potentials; Aged; Atrial Fibrillation; Bepridil; Carbazoles; Carvedilol; Electric Countershock; Electrocardiography; Electrophysiology; Female; Heart Atria; Humans; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Propanolamines; Recurrence; Risk Factors

2005
Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
    Journal of cardiovascular pharmacology, 2013, Volume: 61, Issue:1

    Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biphenyl Compounds; Carbazoles; Carvedilol; Disease-Free Survival; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Japan; Kaplan-Meier Estimate; Long QT Syndrome; Male; Middle Aged; Propanolamines; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Tetrazoles; Time Factors; Treatment Outcome

2013

Other Studies

8 other study(ies) available for bepridil and carvedilol

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
    Bioorganic & medicinal chemistry letters, 2004, Sep-20, Volume: 14, Issue:18

    Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical

2004
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
    Journal of medicinal chemistry, 2009, Jan-22, Volume: 52, Issue:2

    Topics: Chromatography, Liquid; Drug Design; Humans; Likelihood Functions; Microsomes, Liver; Pharmacokinetics; Tandem Mass Spectrometry

2009
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011